Thursday, January 29, 2015 3:13:59 PM
And despite the shape being 'long & wormy' (to quote a great mind) - the Ebola virus (like other viruses) is actually quite structurally simple.
It is a simple, helical tube of regularly shaped and spaced protein subunits, surrounded by a regular and evenly spaced set of glycoprotein spikes:
http://ebola.pictures/Ebola-Structure-Series-annotated.png
And
http://www.rcsb.org/pdb/education_discussion/molecule_of_the_month/images/178-EbolaVirusProteins_EbolaProteins.jpg
The fact that the tube (viral coat) itself can be looped & coiled about some will not change the fact that the ligands should bind to their targets if properly designed.
And if those ligands bind effectively to their targets,.... the Ebolacide should effectively bind to and demolish a virus.
But know what,.... We'll have data supporting or refuting these ideas soon enough,.... USAMRIID is running those tests and if the 'Cides don't work effectively then the argument is settled.
And if they do work,.... those concerns are misguided.
It is a simple, helical tube of regularly shaped and spaced protein subunits, surrounded by a regular and evenly spaced set of glycoprotein spikes:
http://ebola.pictures/Ebola-Structure-Series-annotated.png
And
http://www.rcsb.org/pdb/education_discussion/molecule_of_the_month/images/178-EbolaVirusProteins_EbolaProteins.jpg
The fact that the tube (viral coat) itself can be looped & coiled about some will not change the fact that the ligands should bind to their targets if properly designed.
And if those ligands bind effectively to their targets,.... the Ebolacide should effectively bind to and demolish a virus.
But know what,.... We'll have data supporting or refuting these ideas soon enough,.... USAMRIID is running those tests and if the 'Cides don't work effectively then the argument is settled.
And if they do work,.... those concerns are misguided.
“The two most powerful warriors are patience and time.”
- Leo Nikolaevich Tolstoy
Recent NNVC News
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
